In the last trading session, 7.2 million Blueprint Medicines Corp (NASDAQ:BPMC) shares changed hands as the company’s beta touched 0.84. With the company’s per share price at $127.97 changed hands at $0.12 or 0.09% during last session, the market valuation stood at $8.26B. BPMC’s last price was a discount, traded about -0.21% off its 52-week high of $128.24. The share price had its 52-week low at $73.04, which suggests the last value was 42.92% up since then. When we look at Blueprint Medicines Corp’s average trading volume, we note the 10-day average is 9.45 million shares, with the 3-month average coming to 2.19 million.
Analysts gave the Blueprint Medicines Corp (BPMC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.74. If we narrow down to specifics, the data shows that 0 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 4 recommended BPMC as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight.
Blueprint Medicines Corp (NASDAQ:BPMC) trade information
Instantly BPMC was in green as seen at the end of in last trading. With action 0.14%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 46.72%, with the 5-day performance at 0.14% in the green. However, in the 30-day time frame, Blueprint Medicines Corp (NASDAQ:BPMC) is 29.58% up. Looking at the short shares, we see there were 5.67 million shares sold at short interest cover period of 6.38 days.
The consensus price target for the stock as assigned by Wall Street analysts is 141, meaning bulls need an upside of 9.24% from its current market value. According to analyst projections, BPMC’s forecast low is 132 with 150 as the target high. To hit the forecast high, the stock’s price needs a -17.21% plunge from its current level, while the stock would need to soar -3.15% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 31.87%. The 2025 estimates are for Blueprint Medicines Corp earnings to increase by 34.23%.
BPMC Dividends
Blueprint Medicines Corp is expected to release its next quarterly earnings report on 2025-Apr-30.
Blueprint Medicines Corp (NASDAQ:BPMC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.86% of Blueprint Medicines Corp shares while 109.42% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 110.37%. There are 109.42% institutions holding the Blueprint Medicines Corp stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 10.5758% of the shares, roughly 6.65 million BPMC shares worth $716.45 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 10.4026% or 6.54 million shares worth $704.72 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and T. Rowe Price New Horizons Fund, Inc. . With 2.01 shares estimated at $257.12 million under it, the former controlled 3.11% of total outstanding shares. On the other hand, T. Rowe Price New Horizons Fund, Inc. held about 3.09% of the shares, roughly 2.0 shares worth around $255.59 million.
